Coherus BioSciences Inc. (CHRS) Leaped After Patent Victory

Thursday, 18 May 2017
Coherus BioSciences Inc. (CHRS) announced Tuesday that the Patent Trial and Appeal Board ruled in its favor in a case against AbbVie (ABBV) over U.S. Patent 8,889,135.

Related Videos


Wochit News -   ▶  00:39


Bloomberg Technology -   ▶  02:38

Recent related news

Allergan Inc. (AGN) sold off sharply Monday afternoon, after the U.S. District Court for the Eastern District of Texas ruled that four asserted patents covering...
3 days ago • RTTNews
Benitec Biopharma Ltd’s (ASX:BLT) shares closed 20% higher on Wednesday after securing a new patent related to its hepatitis B program in the U.S. The...
1 day ago • Proactive Investors
LITTLETON, Colo.--(BUSINESS WIRE)--CPI Card Group (Nasdaq: PMTS, TSX: PMTS) (“CPI” or the “Company”), a global leader in financial and EMV® chip card...
3 days ago • Business Wire
LOS ANGELES--(BUSINESS WIRE)--Eos Biosciences announces issuance of second U.S. Patent for its targeted breast cancer therapy, a HER3-targeted Eosome with...
3 days ago • Business Wire
MONTGOMERY, Ala.--(BUSINESS WIRE)--Kowa Pharmaceuticals America, Inc. announced the U.S. District Court, Southern District of New York, has found the U.S. patent...
1 week ago • Business Wire

You might like